Ampath opens second reference lab in Gurgaon

IMT News Desk
IMT News Desk
· 2 min read

The state-of-the-art reference laboratory will offer a wide range of best-in-class diagnostic services with over 2500+ tests 

American Institute of Pathology & Laboratory Sciences (Ampath) has opened its first reference laboratory in Gurgaon as part of its expansion plans in North India. This marks the company’s second reference lab in India. The 7000 sq ft laboratory is equipped with the latest technology platforms capable of delivering quality reports with a quick Turn-Around-Time (TAT). The reference lab will become an independent ecosystem for Delhi and the neighbouring states in North India. 

The newly launched spacious pathology centre serves a comprehensive menu of more than 2,500 tests, performed under the supervision of highly experienced pathologists. The lab offers diagnostic tests in clinical biochemistry, hematology, flow cytometry, clinical pathology, serology, immunology, microbiology, cytology, histopathology, immunohistochemistry, molecular diagnosis, NGS, & Cytogenetics amongst others. These services help in the diagnosis and detection of various diseases affecting different organs and parts of the body which can be extremely vital for the clinician to decide on the treatment protocol. Making quality diagnostics services available to people even in the most remote areas, Ampath is offering a collection centre model in the northern geography. 

Dr Maneesh Bagai, COO, Ampath commented, “We are delighted and pleased to announce the launch of our newest lab in Gurgaon. Working in tandem with achieving our vision, we are proud to have expanded our presence in one of the leading markets and will now be able to serve the population in and around Gurgaon with our automated & best-in-class, advanced test profiles with high-quality standards. Ampath is at the forefront of providing evidence-based, focused healthcare services in South Asia. We strive to provide top-notch services, innovation and quality-driven results in all our endeavors.” 

Dr Pankaj Karwa, Head of Lab Operations, Ampath said, “We are elated on opening a new lab and expanding our presence in the North where we will be offering a wide spectrum of diagnostic tests. With high-tech equipment and a team of skilled professionals, we hope to service our customers continually and efficiently with quality and enhanced healthcare services.” 

 

Read Next

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk
DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 
News
June 11, 2026

DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 

DFE Pharma has earned its third consecutive Gold Medal from EcoVadis, the world leader in corporate sustainability assessments, in recognition of its strong performance in the four themes rated: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. This distinction places DFE Pharma in the top 5% of companies, reflecting the company’s focused efforts to […]
Article by: IMT News Desk
Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India
News
June 11, 2026

Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India

Oval Advanced Fertility Care and Merck Specialities Private Limited, the Indian healthcare arm of Merck KGaA, Darmstadt, Germany and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MOU).   India’s IVF market, valued at approximately USD 2.35 billion in 2024, is projected […]
Article by: IMT News Desk
Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global
News
June 11, 2026

Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global

Bengaluru-based precision oncology startup 4baseCare has raised ₹128 crore in its ongoing Series B funding round to expand its hospital-linked genomics laboratory network globally and scale its AI-powered precision oncology platform, OncoTwin. The latest funding round, which follows a first close of ₹90 crore co-led by Ashish Kacholia and Lashit Sanghvi with participation from existing […]
Article by: IMT News Desk